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Rescuing the Failing Heart
by Targeted Gene Transfer
Yoshiaki Kawase, MD, Dennis Ladage, MD, Roger J. Hajjar, MD
New York, New York
Congestive heart failure is a major cause of morbidity and mortality in the United States. Although progress in
conventional treatments is making steady and incremental gains to decrease heart failure mortality, there is a
critical need to explore new therapeutic approaches. Gene therapy was initially applied in the clinical setting for
inherited monogenic disorders. It is now apparent that gene therapy has broader potential that also includes
acquired polygenic diseases, such as congestive heart failure. Recent advances in understanding of the molecu-
lar basis of myocardial dysfunction, together with the evolution of increasingly efficient gene transfer technology,
have placed heart failure within the reach of gene-based therapy. Furthermore, the recent successful and safe
completion of a phase 2 trial targeting the sarcoplasmic reticulum Ca2 ATPase pump along with the start of
more recent phase 1 trials are ushering in a new era of gene therapy for the treatment of heart failure.
(J Am Coll Cardiol 2011;57:1169–80) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.023a
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ingly sound scientific basis for cautious human evaluation of
additional gene therapy strategies. Furthermore, the ana-
tomical compartmentalization of the heart and its accessi-
bility by surgical and percutaneous approaches renders the
myocardium a highly amenable target system for gene
therapy. Improvement in our understanding of the molec-
ular mechanisms of heart failure (HF), along with the
development of novel and safer vectors for gene delivery, has
led to the identification of novel targets that are difficult to
manipulate pharmacologically but may be more amenable to
gene therapy.
In this review, we highlight new strategies for the
treatment of HF by gene transfer focusing on the vectors,
targets, and delivery methods.
Gene Delivery
Nonviral vectors. Nonviral vectors can be loosely grouped
as plasmid DNA, liposome-DNA complexes (lipoplexes),
and polymer-DNA complexes (polyplexes) (1). Oligonucle-
otides and their analogues, either alone or in complexes, are
also an example of nonviral vector-mediated gene transfer.
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i2010, accepted November 20, 2010.Although myocardial plasmid–mediated gene transfer is
relatively inefficient (2), it has been the vector system on
which several therapeutic angiogenesis trials have been
based. In this setting, transient secretion of angiogenic
factors by a modest number of gene-modified cells is
sufficient for the desired phenotypic effect.
More recently, degradable polymer nanoparticles have
been developed for gene delivery. Nanoparticle systems,
polymers of hydroxy acids such as poly(lactic-co-glycolic)
acid, which are U.S. Food and Drug Administration ap-
proved, have the capacity to release DNA material over
prolonged time frames. Nanoparticles are well suited for
gene delivery applications because they have a large nucleic
acid cargo capacity and avoid the safety risks of standard
adenoviral transfection (3). With the development of de-
gradable polymer nanoparticles made of end-modified
poly(-amino ester)-amino ester that are easy to synthesize
nd can self-assemble with DNA to form stable nanopar-
icles that degrade via hydrolytic cleavage of backbone ester
roups, there is now hope that these nanoparticles can be
sed in cardiac gene transfer.
iral vectors. The predominant use of viral vector systems
n pre-clinical models of gene therapy is a reflection of the
ncreased gene transfer efficiencies achievable with these
ystems. The most commonly used viral vector systems are
overed in the following discussion, and in Table 1, we list
he 3 most commonly used vectors for cardiovascular gene
ransfer.
denoviral vectors. Recombinant human adenoviral vec-
ors are the most commonly used vectors in experimental
ene therapy models. The strengths of this vector system
nclude the relative ease of production, the high functional
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target cell tropism, particularly
within the cardiovascular system.
All major cardiac cell types can
be efficiently transduced by ad-
enoviral vectors, both in vitro
and in vivo. With regard to car-
diomyocytes, efficient in vivo
transduction has been demon-
strated in gene therapy models of
several mammalian species (4,5).
The adenovirus uses the Cox-
sackie adenovirus receptor to in-
tegrate into the cell. Physical ap-
proaches to enhance adenoviral
gene transfer in the myocardium
include methods that rely on
catheter-based or surgically in-
duced transcoronary pressure gra-
dients to increase gene delivery to
the myocardium (6) or the appli-
cation of ultrasound energy to dis-
perse the circulating vector as it
traverses the myocardium (7).
Although adenoviral vectors are useful research tools,
translation to clinical applications has been challenging for
a number of reasons. Adenoviral vectors have a widely
appreciated capacity for evoking intense immune and in-
flammatory reactions, which limits their expression. Addi-
tional constraints of these vectors include the promiscuity
with which they infect all organs (especially the liver), even
when delivered in a distant organ.
Several approaches have been explored to increase the
biosafety of adenoviral vectors. These include vectors with
increasingly reduced amounts of parental virus genes such
that current generation “gutted” adenoviral vectors are
devoid of almost all of these. This development results in
decreased production of toxic viral proteins and may extend
transgene expression over time.
Adeno-associated virus (AAV) vectors. Recombinant
adeno-associated virus (rAAV) vectors are derived from the
dependent parvovirus (8). This vector system has a number
of clinically favorable attributes such as the lack of parental
Abbreviations
and Acronyms
AAV  adeno-associated
virus
AC  adenylyl cyclase
-AR  beta-adrenergic
receptor
GRK  G protein–coupled
receptor kinase
HF  heart failure
LV  left ventricular
PLN  phospholamban
PP1  protein
phosphatase 1
PPI  protein phosphatase
inhibitor
SDF  stromal-derived
factor
SERCA2a  sarcoplasmic
reticulum Ca2 ATPase
SR  sarcoplasmic
reticulum
Comparison of Major Viral Vector SystemsTable 1 Comparison of Major Viral Vector S
Adenovirus
Genome dsDNA
Insert capacity, kb 7–30
Integration No
Pattern of transgene expression Transient
Host-vector interactions Cytotoxic and immuno
Clinical trial approved YesAAV  adeno-associated virus; dsDNA  double stranded deoxyribonucleic a
stranded ribonucleic acid.agent pathogenicity and vector-related cytotoxicity, minimal
immunogenicity, and the capacity for stable long-term
transgene expression through genomic integration and/or
stable episome maintenance. Major limitations of rAAV
vector systems include the production of high-titer vector
stocks, a limited packaging capacity, and the existence of
neutralizing antibodies in human populations.
AAVs have many characteristics that make them partic-
ularly well suited as vectors for cardiac gene transfer. First,
AAV effectively transfects slowly or nondividing cells,
making them ideal vectors for gene transfer to cardiomyo-
cytes. Second, AAV is not known to cause human disease,
suggesting that the risks to patients, health care workers,
and the public at large are low. AAV vectors contain no viral
genes, further increasing their safety, and decreased immune
responses, thereby allowing them to persist and express
transgenes in cells in the long term (4 years in some trials
[9]). A total of 12 different AAV serotypes are known,
including AAV1 through AAV12, each with different tissue
tropisms (10). AAV1 and AAV6 have been shown to
ransduce skeletal and cardiac muscle efficiently, whereas
AV9 has very high tropisms to the heart. Dimeric or
elf-complementary molecules (self-complementary adeno-
ssociated virus [scAAV]) spontaneously re-anneal, allevi-
ting the requirement for host-cell DNA synthesis. Mc-
arty et al. (11) engineered such vectors and found that
hese scAAV resulted in rapid and higher levels of transgene
xpression than a conventional single-strand vector. These
ovel scAAV vectors represent a biochemical intermediate
n rAAV transduction and should provide new insights into
he biology of vector transduction. However, the cassette
izes must be half of a normal-size, single-strand vector (i.e.,
.3 kb), which further limits the number of genes that can
e used with scAAV.
Limiting expression of the transgene to the heart is
ndoubtedly beneficial for clinical applications. One way to
chieve expression exclusively in the heart is to use a
ardiomyocyte specific promoter. However, although this is
n attractive approach, it would be more desirable to achieve
ardiomyocyte-specific expression by targeting the vector
tself to the heart. Vector targeting will likely allow the use
f lower vector doses compared with nontargeted AAV.
nfusing lower vector doses are not only preferable from a
s
Vectors
AAV Lentivirus
ssDNA ssRNA
4.8 7–10
No Pseudo-random
Long term Long term
Minimally immunogenic Minimally immunogenic
Yes Noystem
geniccid; ssDNA  single stranded deoxyribonucleic acid; ssRNA  single
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March 8, 2011:1169–80 Heart Failure and Gene Transferproduction point of view but, more importantly, may be
safer in patients. It was previously shown that chimeric
viruses (i.e., virions composed of capsid proteins of 1
erotype) have distinct transduction profiles (12). Based on
hese results, viruses composed of hybrid capsid proteins
i.e., capsid proteins encoded by amino acid segments of
everal serotypes) should result in distinct tropism. To
dentify hybrid viruses that can selectively transduce car-
iomyocytes in vivo, a combinatorial approach has been
sed whereby the generation of a library of diverse AAV
ariants, obtained by DNA shuffling, with an enrichment
f cardiotropic AAV variants by directed evolution are
ombined (13).
etroviral and lentiviral vectors. Retroviral vectors based
n the Moloney murine leukemia virus have been used
idely in pre-clinical models. More recently, this vector was
sed in the successful French trial of gene therapy for
-linked severe combined immunodeficiency (14). The
ain limitations of retroviral vectors are an inability to
ransduce nondividing cells such as cardiac myocytes. As a
esult, many investigators have sought to overcome this
lock by inducing the in vivo proliferation in target cells or
y using an ex vivo strategy (2).
Lentiviral vectors, based on the human immunodefi-
iency virus type 1 (15), transduce target cells by genomic
ntegration. In contrast to retroviral vectors, these vectors
re capable of transducing mitotically quiescent cells, a
roperty that broadens the range of target cells, particularly
ithin the cardiovascular system. Vector modifications ad-
ressing biosafety concerns associated with contemporary
uman immunodeficiency virus type 1–derived lentiviral
ectors include the deletion of all accessory protein genes
rom the packaging system, separation of packaging ele-
ents into multiple plasmids, and the use of a chimeric 5=
ong terminal repeat and a self-inactivating 3= long terminal
epeat in the vector plasmid (16). The experimental use of
his relatively new vector system in pre-clinical models is
apidly expanding, and its potential application for human
ene therapy has not yet been explored. The strengths of
his system include the ability to confer long-term stable
ransgene expression. The major limitations relate to bio-
afety. Recently, premalignant clonal T-cell proliferation
eveloped in 3 of 10 children from the French X-linked
evere combined immunodeficiency trial that was directly
ttributable to dysregulation of a gene at the proviral
ntegration site (17). The risk of insertional mutagenesis
ith integrating vector use had previously been considered
inimal, a view now under revision.
esign of the Expression Cassette
he basic components of an expression cassette include
romoter/enhancer elements, the gene(s) of interest, and an
ppropriate mRNA-stabilizing polyadenylation signal.
ther frequently used cis-acting elements include internalibosome entry site sequences to allow expression of 2 oenes without the need for an additional promoter and
ntrons and post-transcriptional regulatory elements to im-
rove transgene expression.
Tissue-specific promoters can be used to restrict trans-
ene expression to the desired target cell population and
void unintended cells such as antigen-presenting cells. For
xample, cardiomyocyte-specific promoters such as alpha-
yosin heavy chain have been used to restrict gene expres-
ion to the myocardium. Similarly, the smooth muscle–
pecific promoter SM22 has been demonstrated to restrict
gene expression to cells of this type.
In a number of instances, it is desirable to have precise
regulation of a therapeutic gene expression in vivo. Natural
and synthetic enhancer-promoters can be used to drive gene
transcription in a temporal, spatial, or environmental signal-
inducible manner in response to heat shock, hypoxia,
radiation, chemotherapy, or epigenetic agents. Hypoxia,
intravascular shear stress, and left ventricular (LV) strain
have all been used in models of this type of regulation. In
the setting of HF, a regulatable system would be important
if the gene of interest needs to be turned on or off for a short
period of time. This would include genes driving angiogen-
esis or stem cell recruitment or expansion.
Targeted Nucleases
Meganucleases and zinc finger proteins can be engineered to
induce double-strand breaks at specific DNA sequences
(18,19). These breaks are repaired by homologous recom-
bination or by nonhomologous end-joining, which results in
insertions or deletions of a few base pairs. They can then be
used to restore the normal reading frame of a gene with a
specific mutation. Similarly, engineered zinc finger protein
transcription factors can specifically activate or repress
virtually any gene. Meganucleases and zinc finger proteins
have been used to target dystrophin mutations and vascular
endothelial growth factor expression by gene transfer (20).
With the ever-expanding genetic mutations in dilated and
hypertrophic cardiomyopathies (21), these nucleases can be
used in the future to repair DNA in the affected organs by
gene therapy.
Methods of Vector Delivery
In addition to the major advances in engineering vehicles for
myocardial gene therapy, novel delivery methods have been
developed to specifically target the heart. Regardless of the
delivery methods, chemical approaches that include the use
of vasodilatory and permeabilizing agents have been used to
facilitate transfer of vector from the vascular lumen to the
myocardium (22). In fact, several agents that increase the
permeability of the vascular bed have been used in pre-
clinical trials including nitroglycerin, nitroprusside, sero-
tonin, bradykinin, histamine, substance P, and vascular
endothelial growth factor (23). Clinically and in the setting
f HF, these agents must be used with caution so as not to
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Heart Failure and Gene Transfer March 8, 2011:1169–80decrease systemic blood pressure. The multiple methods of
gene delivery are illustrated in Figures 1 and 2.
Antegrade injection. Antegrade injection in the coronary
circulation is the most straightforward way to deliver vectors
to the myocardium. It has the potential to homogeneously
deliver the vector to the whole myocardium. There are
multiple techniques of antegrade coronary injection.
ANTEGRADE INJECTION WHILE BLOCKING THE CORONARY
ARTERY. This method, depicted in Figure 1A, involves
nflating a balloon to block the coronary flow while injecting
ownstream of the balloon. This method allows flow of the
iral vector to occur without dilution; however, blocking
ntegrade flow may not be well tolerated, even for a short
eriod of time.
Figure 2 Retrograde Injections of
Vectors Through Coronary Vessels
(A) Retrograde infusion through the coronary sinus while the coronary artery is
blocked. (B) Intramyocardial injection from a catheter within the coronary vein.
Abbreviations as in Figure 1.Figure 1 Antegrade Injections of
Vectors Through Coronary Vessels
(A) Antegrade injection while blocking the coronary artery. (B) Antegrade injec-
tion while not blocking the coronary artery. (C) Recirculating flow. AIV  ante-
rior interventricular vein; CS  coronary sinus; LAD  left descending coronary
artery; LCX  left circumflex coronary artery.
n
T
m
a
i
m
c
f
i
H
p
a
e
(
e
s
a
c
m
e
c
i
a
s
w
v
R
T
s
s
r
b
c
1173JACC Vol. 57, No. 10, 2011 Kawase et al.
March 8, 2011:1169–80 Heart Failure and Gene TransferPROLONGED ANTEGRADE INJECTION WITHOUT BLOCKING
THE CORONARY ARTERIES. This simple yet effective tech-
ique, depicted in Figure 1B, works best with AAV vectors.
here is no obstruction of flow, and it can be an optimal
ethod for patients with HF who may not tolerate coronary
rtery blockade. Even though this method of antegrade
njection does not infect all cardiomyocytes (60% of
yocytes), it follows the normal pattern of flow in the
oronary arteries and has been shown to improve ventricular
unction in a large animal model of HF (24). Of note, this
s the method that was used clinically in patients with severe
F receiving AAV1 sarcoplasmic reticulum Ca2 ATPase
(SERCA2a).
CIRCULATORY PERFUSION TECHNIQUE. The V-Focus (Os-
rey Medical Inc., St. Paul, Minnesota) delivery system
llows a minimally invasive, percutaneous procedure to
stablish isolated regional perfusion of the myocardium
Fig. 1C). It enables a closed circuit to be percutaneously
stablished between the coronary arteries and the coronary
inus. Through percutaneous catheters, it selectively isolates
nd circulates the gene transfer agent through the coronary
irculation. Adequate oxygenation of the myocardium is
aintained in part by circulating the perfusate through an
xtracorporeal membrane oxygenation system. Once a
losed circuit is established, the vector is directly injected
nto the circuit and circulates through the myocardium for
pproximately 10 min. This technique has allowed wide-
pread transduction of SERCA2a in an ovine model of HF
ith a substantial increase in contractility, both with adeno-
iral and AAV gene transfer (25,26).
etrograde injection. RETROGRADE DELIVERY THROUGH
HE CORONARY SINUS. Using the coronary vein, which is
disease free in most cases, for the route to deliver the
therapeutic material is attractive, especially in the clinical
setting in which the patient has a diseased coronary artery
(Fig. 2A) (27–29). The increase in efficacy has been
achieved by pressure-regulated retroperfusion using a spe-
cialized device in this approach. Retrograde infusion of
vector via the coronary veins constitutes a novel catheter-
based technique for myocardial gene delivery, and in studies
pioneered by Boekstegers et al. (27), it was shown to be
uperior to antegrade coronary injections. However, other
tudies showed that antegrade coronary injection was supe-
ior to retrograde injection (30). However, this method can
e somewhat problematic in patients who may not tolerate
oronary occlusion.
TRANSCATHETER DEVICE. A composite catheter system
(TransAccess, Medtronic Inc., Minneapolis, Minnesota)
incorporates a phased-array ultrasound tip for guidance and
a sheathed extendable nitinol needle for transvascular myo-
cardial access that is advanced from the coronary sinus
retrograde (Fig. 2B). A microinfusion catheter is advanced
through the needle, deep into remote myocardium, and the
autologous cell-hydrogel suspension is injected into normal
heart. This allows the delivery of vectors directly intospecific areas of the myocardium accessible through the
coronary sinus (31).
Direct injection. Direct injection of the vector into the
myocardium can be achieved surgically or percutaneously. It
overcomes numerous potential drawbacks that can be en-
countered with the intravascular route including the first-
pass effect of the liver and spleen, the effect of neutralizing
antibodies, the T-cell response, and the impermeability of
the endothelial barrier. Surgical gene transfer can be per-
formed via a subxiphisternal or transthoracic approach and
can be an attractive approach when the myocardium is easily
accessible as during cardiothoracic surgeries (Fig. 3A).
Catheter-based needle endomyocardial injection can be
performed with several types of catheters and under differ-
ent guidance modalities including fluoroscopy, electromag-
netism, and 3-dimensional mapping systems (Fig. 3B).
Both surgical and percutaneous approaches have limited
vector delivery secondary to the restricted area of injection
and the leakage at the site of the myocardial injection.
Pericardial delivery. The pericardial sac is a closed space in
close proximity to the myocardium and is accessible to both
surgical and percutaneous delivery (Fig. 3C). Vectors in this
space preferentially transduce the pericardial cells with
minimal myocardial expression. A percutaneous pericardial
approach allows safe and effective pericardial access appro-
priate for the delivery of therapeutic agents.
The optimal method of delivery depends largely on the
proportion of target tissue to be genetically modified. Focal
transduction might be desired to salvage an ischemic area,
whereas diffuse gene expression is more likely to reverse
global myocardial dysfunction.
Surgical delivery. Surgical delivery in animal models usually
involves an open chest procedure in which the heart is arrested
in hypothermia or the aorta and pulmonary arteries are
cross-clamped in rodent models (6,32,33) or the animals are
placed on bypass in large animal models. On bypass, the viral
vector can be delivered in either an antegrade or retrograde
fashion (34). More recently, Bridges et al. (35,36) developed a
complete surgical isolation of the heart in situ with retrograde
administration of vectors, which results in very high myocyte
transduction efficiency. However, it is not clear whether pa-
tients with advanced HF could tolerate such a procedure for
gene transfer.
Targets
The past 20 years witnessed significant evolution in our
understanding of the pathophysiology of HF in its molec-
ular and cellular dimensions, which broadened the scope of
interventions available for gene therapy. We discuss in this
section some of the most important systems targeted to
restore the function of failing cardiomyocytes.
For targets to be validated, it is important that they rescue
function in animal models when HF has been already
established, that the rescue is not associated with arrhyth-
mogenesis, and that a gene-dose effect is established (i.e.,
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Heart Failure and Gene Transfer March 8, 2011:1169–80with increasing expression of the gene of interest, there is a
concomitant improvement in function).
In Figure 4, the various targets in excitation contraction
coupling are presented.
Targeting the -adrenergic system. The -adrenergic
ystem is affected by multiple alterations including
-adrenergic receptors (-ARs) down-regulation, up-
egulation of -AR kinase, and increased inhibitory G
rotein function. These alterations lead to desensitization of
he -ARs and decreased signaling through their pathway.
everal gene-based experiments tested the hypothesis that
enetic manipulation of the myocardial -AR system can
nhance cardiac function.
OVEREXPRESSION OF -AR. Overexpression of -AR was
initially tested as a simple way to overcome -AR down-
regulation. Transgenic mice overexpressing human 1-ARs
ad severe cardiomyopathy (37). This finding reinforces the
ypothesis that -AR down-regulation is a protective
mechanism in the failing heart. In contrast, mice with
cardiac overexpression of 2-AR demonstrated increased
basal myocardial AC activity with increased LV function
(38). Both direct and intracoronary myocardial delivery of
adenovirus containing the human 2-AR transgene resulted
n enhanced cardiac performance in rabbits (39,40).
INHIBITION OF G PROTEIN–COUPLED RECEPTOR KINASE
(GRK). The interaction between activated -ARs and
proteins is regulated by kinases that modulate the
eceptor activity by phosphorylation of its carboxyl termi-
us. Agonist-dependent desensitization is mediated by a
amily of GRKs that phosphorylate the agonist-occupied
eceptors, resulting in functional uncoupling. GRK2 is the
ost expressed GRK in the heart. It has been implicated in
he pathogenesis of dysfunctional cardiac -AR signaling,
ccounting for a deleterious activity in the failing heart (41).
tudies in mice in which HF was induced by a myocardial
nfarction showed that selective GRK2 ablation 10 days
ost-infarction resulted in increased survival, halted ventricular
emodeling, and enhanced cardiac contractile performance
42). A peptide termed ARKct capable of inhibiting GRK2-
mediated -AR desensitization has been evaluated in vivo in
nimals. Using intracoronary adenovirus-mediated ARKct
transgene delivery to rabbits 3 weeks after induced myocardial
infarction demonstrated a marked reversal of ventricular
dysfunction (43).
ACTIVATION OF CARDIAC AC. Although detrimental out-
omes were demonstrated with multiple elements of the
-adrenergic system used to improve the expression of cyclic
adenosine monophosphate, activation of AC type VI seems
to have a unique favorable profile. Overexpression of AC
type VI in transgenic mice resulted in improved cardiac
function in response to adrenergic stimulation along with
increased cyclic adenosine monophosphate production in
isolated cardiac myocytes. Importantly, AC type VI had aFigure 3 Ventricular Injections of Vectors
(A) Direct surgical injections. (B) Catheter-based intracardiac injections.
(C) Pericardial delivery.neutral effect on basal heart function and was not associated
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March 8, 2011:1169–80 Heart Failure and Gene Transferwith any structural heart abnormalities (44). In a pacing
odel of HF in pigs, intracoronary delivery of adenovirus
ncoding AC type VI resulted in improved LV function
nd remodeling, associated with increased cyclic adeno-
ine monophosphate–generating capacity (23). The fa-
orable effects of AC type VI in pre-clinical studies are
ncouraging, and this approach is currently under in-
estigation for initiation of clinical trials in patients with
F (45).
argeting Ca2 cycling proteins. Ca2 plays a crucial role
in contraction and relaxation phases of the cardiac cycle
(Fig. 1). Ryanodine receptors are proteins forming a link
between the T tubules in the cardiomyocytes and the
sarcoplasmic reticulum (SR). In a process known as Ca2-
induced Ca2 release, depolarization activates voltage-
operated L-type Ca2 channels of the T tubule to allow
a2 entry into the cardiomyocyte. Ca2 reaches the
yanodine receptor protein, modifying its molecular config-
ration, which in turn opens the Ca2 release channel of the
R, releasing Ca2 into the cytosol. This process greatly
ncreases the concentration of Ca2 in the cytosol, allowing
Figure 4 Targets Within Cardiac Myocytes
Excitation-contraction signaling in cardiomyocytes with emphasis on targets for ge
tems is illustrated. AC  adenylyl cyclase; AMP  adenosine monophosphate; An
phosphate; DAG  diacylglycerol; ET  endothelin; FKB12  FK506-binding prote
G protein q; Gs  stimulatory G protein; IP3  inositol triphosphate; NE  norepi
PLCB  phospholipase C beta; PP1  protein phosphatase 1; PPI  protein phos
ATPase.it to interact with troponin C, triggering the contraction Gprocess. Relaxation occurs when Ca2 detaches from tro-
ponin C and is either taken up by the SR via the action of
SERCA2a or extruded from the cardiac cell by the sar-
colemnal Na/Ca2 exchanger. Phospholamban (PLN) is a
protein implicated in the regulation of SERCA2a activity.
In its unphosphorylated form, PLN can inhibit SERCA2a.
In contrast, phosphorylation of PLN relieves its inhibitory
effect and results in increased SERCA2a activity with
improved Ca2 handling. Protein phosphatase 1 (PP1) is a
type of serine/threonine phosphatase that has a major role in
dephosphorylation of PLN in the heart (46–48). In partic-
ular, stimulation of the -adrenergic axis induces phosphor-
lation of a phosphatase protein inhibitor 1 (PPI) resulting in
P1 inhibition and enhancement of myocardial contractile
unction (46–48). HF is characterized by multiple defects in
a2-handling proteins with impaired SR Ca2 loading and
release. Reversal of those defects by gene therapy techniques
has shown very promising results. We review the main aspects
of those novel therapies in this section.
OVEREXPRESSION OF SERCA2a. More than 20 years ago,
rapy. Interplay between calcium handling (purple) and -adrenergic (blue) sys-
angiotensin II; ATP  adenosine triphosphate; cAMP  cyclic adenosine mono-
; Gi  inhibitory G protein; GRK2  G-protein–coupled receptor kinase 2; Gq 
e; PDE  phosphodiesterase; PKA  protein kinase A; PLC  phospholipase C;
e inhibitor; RyR  ryanodine receptor; SERCA2a  sarcoplasmic reticulum Ca2ne the
g II 
in 12.6
nephrin
phataswathmey et al. (49) first reported that calcium cycling is
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Heart Failure and Gene Transfer March 8, 2011:1169–80abnormal in human HF and was found to be partially due to
decreased SERCA2a activity regardless of the etiology of
the HF (50–52). Improvement in cardiac contractility after
gene transfer of SERCA2a has been demonstrated in a large
number of experimental models of HF (54,55). More
importantly, long-term overexpression of SERCA2a by
intracoronary delivery of AAV carrying SERCA2a has been
associated with preserved systolic function and improved
ventricular remodeling in a swine volume-overload model of
HF (24). Beyond their effects on enhancing contractility,
SERCA2a gene transfer has been shown to restore the
energetics state of the heart both in terms of energy supply
and utilization to decrease ventricular arrhythmias and to
enhance coronary flow through activation of endothelial
nitric oxide synthase in endothelial cells (56–59).
PLN INHIBITION. Another approach to improve Ca2 han-
ling involves inhibition of PLN. Decreasing PLN in
uman cardiac myocytes showed an improvement in con-
raction and relaxation velocities similar to the benefit seen
ith gene transfer of SERCA2a (60). Silencing of PLN
xpression in a sheep HF model resulted in improved
ERCA activity along with improved systolic and diastolic
V function (26). In addition to these conventional gene
herapy strategies, RNA interference therapy was used for
he first time in a model of cardiac disease, specifically in
ats with HF, in an attempt to suppress PLN expression. An
AAV-RNA interference vector generated stable cardiac
roduction of a regulatory RNA sequence, which in turn
uppressed PLN expression. SERCA2a protein was subse-
uently increased accompanied by restoration of systolic and
iastolic cardiac function (61).
ACTIVE PPI AND INHIBITION OF PPL. HF is associated with
levated PP1 activity in humans resulting in dephosphory-
ation of PLN. Overexpression of PP1 or ablation of PPI in
urine hearts has been associated with decreased -AR–
mediated contractile responses, depressed cardiac function,
and premature death consistent with HF (46–48). Expres-
ion of a constitutively active PPI in transgenic mice led to
P1 inhibition with increased phosphorylation of PLN and
mproved cardiac contractility. A recent study on transgenic
ice expressing active PPI confirmed the relationship be-
ween phosphorylation of PLN and SERCA2a activity. PPI
xpression ameliorated ischemia/reperfusion-induced injury
y reducing the infarct size and improving contractile
ecovery in addition to decreasing biomarkers of apoptosis
nd endoplasmic reticulum stress response (46–48).
S100A1. S100 is a multigenic family of Ca2-modulated
roteins implicated in intracellular and extracellular regula-
ory activities. S100A1 is the most abundant S100 protein
soform in the heart. It promotes cardiac contractile and
elaxation function through enhancing the activity of both
yanodine receptors and SERCA2a (62). In a rat model of
F, AAV6-mediated long-term expression of S100A1,
esulted in a sustained in vivo reversal of LV dysfunction
nd remodeling (63,64). rargeting cell death. Apoptosis is a process of pro-
rammed cell death that is involved in normal organ
evelopment. In animal models of acute and subacute
schemia/reperfusion, overexpression of the antiapoptotic
rotein Bcl-2 or akt reduces the rate of cardiomyocyte
poptosis and improves heart function (49). Despite the
arly encouraging results in animal studies, antiapoptotic
trategies face multiple challenges before being considered
or human trials. There remain some uncertainties about the
eliability of the techniques currently used to estimate the
ate of apoptosis (53). In addition, the loss of the normal
ellular regulation role provided by apoptosis can generate a
erious risk of malignant cellular proliferation and autoim-
une injuries. Finally, although ischemia/reperfusion injury
eems to be amenable to intervention, it is less clear whether
ther forms of cardiac injury such as hypertrophy and HF
an benefit from antiapoptotic strategies.
oming of stem cells. It has been well established that
amaged and inflamed tissues send out signals to attract
tem cells to the injured tissue, and many of these signals
ave been identified, including stromal-derived factor
SDF)-1. There has been growing evidence that SDF-1:
XCR4 (its receptor) axis plays an important role in
egulating myocardial repair after ischemic injury. SDF-1
as been shown to be increased after myocardial ischemia,
nd several studies have shown that enhancing SDF-1 levels
round the infarct improves myocardial remodeling after
nfarction. Currently, the strategy of delivering SDF-1
aked DNA by percutaneous measures to the peri-infarct
rea is being used clinically (65).
ranslating Pre-Clinical Results
o Designing Clinical Trials
nce a target is validated in cells, rodents, and large animal
odels; the appropriate vector has been identified; and a
oute of delivery is chosen, a number of challenges remain
efore starting clinical trials. These include evaluation of the
mmune response, clinical parameters to be examined, and
valuating the risk of arrhythmias.
mmune response. One of the challenges with viral gene
ransfer is the pre-existence of neutralizing antibodies. In
ifferent studies, it has been shown that about a significant
roportion of adults are seropositive for AAV2 (as much
s 80%), AAV1 (50%), AAV5 (40%), and AAV6
30%) (66,67). The presence of pre-existing antibodies
an have considerable implications for cardiovascular gene
herapy because it has been shown in several studies that
hese AAV-specific antibodies are neutralizing (66,67) and
an severely compromise the utility of this approach. These
esults highlight the necessity to determine neutralizing
ntibody titers against the specific vector used in the patient
opulation.
Another issue that can occur is that cells may transiently
xpress AAV capsid protein on their cell surface. T-cell
esponse could occur in any organ, but the greatest concern
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March 8, 2011:1169–80 Heart Failure and Gene Transferis for the liver or the heart (site of injection). This response
is dose dependent, and in clinical trials to treat hemophilia
or lipoprotein lipase deficiency, higher doses (1013 viral
genomes) were associated with activation of capsid-specific
T cells and elimination of the transgene (68,69). In clinical
rials, to evaluate the potential development of a T-cell
esponse, it is important to use an ELISPOT assay to detect
nti-AAV capsid T-cell responses (interferon- release
hen a patient’s peripheral blood monocytes are exposed to
apsid peptide).
valuation of clinical parameters after gene trans-
er. It is critical that the assessment of the efficacy of
ene therapy trials be robust enough to detect biological
ignals. In pre-clinical trials and large animal studies,
nvestigators have relied mainly on hemodynamic mea-
urements coupled with noninvasive techniques such as
chocardiography and magnetic resonance imaging
MRI). MRI, which provides the most detailed structural
easurements of the heart, cannot be routinely used in
dvanced HF patients because a majority of them would
ave implantable cardiac defibrillators or biventricular
acemakers. Clinically, invasive monitoring is obviously
ifficult to perform; however, there are a number of
linical measures that can be followed.
rrhythmias. Arrhythmias have been clearly shown to
e a consequence of pharmacological inotropic therapy.
n the context of gene therapy, there may be a number of
easons for arrhythmias to occur. The overexpression or
nock down of specific genes such as channels and ionic
ransporters may induce changes in electrical remodeling
hat can predispose the cells to arrhythmias. In addition,
nhomogeneous expression within the myocardium can
nduce areas of heterogeneously contracting cardiomyo-
ytes that can also lead to arrhythmias. It is therefore
ssential that in pre-clinical studies, detection of arrhyth-
ias be thoroughly studied after gene transfer using
olter monitors or implantable continuous monitoring.
linically, it would be important to protect the patient
eceiving the gene therapy product with an implantable
ardiac defibrillator.
Major Clinical Trials in Gene Therapy for Heart FailureTable 2 Major Clinical Trials in Gene Therapy for Heart Failure
Trial Target n
CUPID (Calcium Up-Regulation by
Percutaneous Administration of
Gene Therapy in Cardiac Disease)
SERCA2a 39
SERCA2a Gene Therapy in LVAD Patients SERCA2a 16
AGENT-HF (AAV6-CMV-Serca2a GENe Therapy
Trial in Heart Failure)
SERCA2a 30
AC6 Gene Transfer for Congestive Heart Failure Adenylyl cyclase-6 72
Study to Evaluate the Safety of a Single
Escalating Dose of ACRX-100 in Adults
With Ischemic Heart Failure
SDF-1 16AAV  adeno-associated virus; HF  heart failure; LVAD  left ventricular assist device; SDF  stromal-dlinical Trials
espite the initial hope that gene therapy had at its
nception, the failures of the clinical trials coupled with the
erious adverse events brought the field close to collapse
0 years ago. The well-publicized complications included
he death a patient with a mild form of the monogenic
isorder ornithine transcarbamylase deficiency, which was
aused by multiorgan failure after the injection of a recom-
inant adenovirus (70–72), and the development of new
T-cell lymphomas in 3 of the 10 children with severe com-
bined immunodeficiency after treatment with retroviruses
(14,73–75). However, the field of gene therapy learned valu-
able lessons from these failures and has rebounded recently
with rigorous regulatory barriers along with a new wave of
novel vectors. There is now a growing number of gene therapy
trials for various diseases, most notably inherited blindness
(whereby gene transfer by AAV vectors partially restored vision
in a pediatric patient with Leber’s congenital amaurosis, a
major cause of congenital blindness [76]), cancer, infectious
diseases, monogenic diseases, and cardiovascular diseases.
Specifically, in HF, there are currently a number of trials
ongoing or in the planning stages targeting various path-
ways for rescuing the failing myocardium (Table 2). The
targets that have been taken forward for clinical trials
include SERCA2a, AC type 6, and SDF-1.
The first clinical trial of gene therapy in patients with HF
was launched in the United States in 2007 (77,78). CUPID
(Calcium Up-Regulation by Percutaneous Administration
of Gene Therapy in Cardiac Disease) is a multicenter trial
designed to evaluate the safety profile and the biological
effects of gene transfer of the SERCA2a cDNA by deliv-
ering a recombinant AAV1 (AAV1.SERCA2a) in patients
with advanced HF. Participants in this trial were adminis-
tered a single intracoronary infusion of AAV1.SERCA2a
using an open-label approach (77,78). Cohorts 1 to 4 of 3
patients each received sequentially a single increasing dose
of AAV1.SERCA2a. The 12-month follow-up of these
patients showed an acceptable safety profile (77,78). Im-
provement was detected in several patients, reflected by
Target Population Mode of Delivery/Vector Status
ischemic and nonischemic Intracoronary/AAV1 Phase 2 trial,
completed
anced HF with LVAD,
schemic and nonischemic
Intracoronary/AAV6 Phase 1/2 trial,
enrolling
ischemic and nonischemic Intracoronary/AAV6 Phase 2 trial,
enrolling
ischemic and nonischemic Intracoronary/adenovirus Phase 1/2 trial,
enrolling
ischemic only Intramyocardial/naked DNA Phase 1 trial,
enrollingHF,
Adv
i
HF,
HF,
HF,erived factor; SERCA2a  sarcoplasmic reticulum Ca2 ATPase.
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Heart Failure and Gene Transfer March 8, 2011:1169–80symptomatic (n  5), functional (n  4), biomarker (n  2),
and LV function/remodeling (n  6) parameters. Although
this was a phase 1 study involving a small number of
patients, early results found that AAV1.SERCA2a treat-
ment conferred a quantitative biological benefit. In the
phase 2 trial, 39 patients with advanced HF were random-
ized to receive intracoronary AAV1-mediated SERCA2a
gene delivery (in 1 of 3 doses: low dose, 6  1011
DNAse-resistant particles; middle dose, 3  1012 DNAse-
resistant particles; and high dose, 1 1013 DNAse-resistant
articles) versus placebo. Patient’s symptoms (New York
eart Association functional class, Minnesota Living With
eart Failure Questionnaire, functional status [6-min walk
est, and VO2max]), N-terminal pro–B-type natriuretic
eptide levels, and echocardiographic measures were evalu-
ted over 6 months. Treatment success was determined by
xamining concordant trends in these end points for group-
nd patient-based comparisons as well as clinical outcomes.
he AAV1.SERCA2a high-dose group met the prespeci-
ed criteria for success at the group and individual patient
evels. AAV1.SERCA2a-treated patients, versus placebo,
emonstrated improvement or stabilization in New York
eart Association functional class, Minnesota Living With
eart Failure Questionnaire, 6-minute walk test, VO2max,
-terminal pro–B-type natriuretic peptide levels, and
V end-systolic volumes. Significant increases in time to
djudicated cardiovascular events and a decreased frequency
f cardiovascular events per patient were observed in all
atients receiving AAV1.SERCA2a. No increases in ad-
erse events, disease-related events, laboratory abnormali-
ies, or arrhythmias were observed in AAV1.SERCA2a-
reated patients compared with those receiving placebo.
Two other clinical trials targeting SERCA2a are currently
nrolling patients. The first trial is in patients with advanced
F having received LV assist devices at least 1 month before
reatment and who will receive either AAV6.SERCA2a or
aline solution. This trial is being conducted in the United
ingdom. A second phase 2 single-center, double-blind,
andomized, placebo-controlled, parallel study will be held at
he Pitié-Salpêtrière Hospital Institute of Cardiology, Paris,
rance, with the primary objective to investigate the impact of
AV6-CMV-SERCA2a on cardiac remodeling parameters in
atients with severe HF.
In a separate clinical study, AAV5 encoding human AC
ype 6 is being delivered by intracoronary injection to
atients with congestive HF. Intracoronary delivery of
d5.hAC6 or phosphate-buffered saline in 3:1 randomiza-
ion with dose escalation, The patients will be randomized
n a dose-dependent fashion starting at 3.2  109 viral
particles to 3.2  1012 viral particles in 6 dose groups in a
3:1 randomization (with phosphate-buffered saline being
used for control). The trial is currently enrolling patients.
An additional trial is examining the effects of injecting
SDF-1 directly into the myocardium of patients with
ischemic heart disease. An open-label dose escalation study
to evaluate the safety of a single escalating dose of SDF-1administered by endomyocardial injection to cohorts of
adults with ischemic HF is currently enrolling patients.
SDF-1 naked DNA will be injected directly into the
myocardium at multiple sites via a percutaneous, LV approach.
Conclusions
An increase in our knowledge of molecular mechanisms of
HF along with improved gene therapy technology has led to
substantial efforts in pre-clinical testing of a number of
targets and more recently in the successful completion of a
phase 2 trial in gene therapy for HF. Now that the safety of
AAV vectors has been established for the treatment of HF
along with the efficacy of SERCA2a in the treatment of
HF, the field is now open for testing novel targets that are
pharmacologically difficult to modulate with more advanced
AAV-based vector systems.
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